ARPA-H Advances $33.5 Million Osteoarthritis Project After Animal Therapies Repaired Joints
Updated
Updated · SciTechDaily · May 27
ARPA-H Advances $33.5 Million Osteoarthritis Project After Animal Therapies Repaired Joints
3 articles · Updated · SciTechDaily · May 27
Clinical trials could begin within 18 months after ARPA-H moved the osteoarthritis program into phase two, following animal studies that restored damaged joints to a healthy state.
Two therapies drove the advance: a single injection that slowly releases an adapted FDA-approved drug over months, and a biomaterial implant that recruits the body’s own cells to rebuild cartilage and bone.
Four to eight weeks after treatment, arthritic and injured animal joints recovered, and researchers also reported strong regenerative effects in human cells taken from joint-replacement patients.
The Colorado team from CU Boulder, CU Anschutz and Colorado State says the goal is a minimally invasive, lower-cost alternative to pain management or joint replacement for a disease affecting about one in six adults over 30 worldwide.
It healed animal joints in weeks, but can this therapy succeed in humans without costing a fortune?
With 100+ rival drugs in development, will this new therapy be the one to finally cure arthritis?
Moonshot Medicine: ARPA-H’s $40M Bet on Regenerative Osteoarthritis Cures Nearing Human Trials
Overview
Osteoarthritis (OA) is a major public health problem that affects people of all ages, from grandparents to athletes, making movement difficult and limiting daily activities. The disease can impact any joint, especially the knees, hips, and hands, and its debilitating nature highlights the urgent need for better treatments. Current therapies often fail to cure OA or stop its progression, leaving a critical gap in medical care. This report explains why organizations like ARPA-H are investing in innovative regenerative therapies, aiming to address this gap and improve the lives of those suffering from OA.